A Phase 1, Randomized, Subject Single Blinded, Placebo-Controlled, Single-Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of NSI-189 Phosphate in Healthy Subjects

Trial Profile

A Phase 1, Randomized, Subject Single Blinded, Placebo-Controlled, Single-Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of NSI-189 Phosphate in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs NSI 189 (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; First in man
  • Sponsors Neuralstem
  • Most Recent Events

    • 18 Nov 2011 Actual end date changed from Oct 2011 to Nov 2011 as reported by ClinicalTrials.gov.
    • 27 Oct 2011 Status changed from active, no longer recruiting to completed.
    • 12 Sep 2011 Trial has almost reached completion, as reported in a Neuralstem media relase.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top